Barclays PLC reaffirmed their overweight rating on shares of Thermo Fisher Scientific Inc (NYSE:TMO) in a research report report published on Monday. The firm currently has a $200.00 target price on the medical research company’s stock, up from their previous target price of $190.00.

A number of other research firms have also recently issued reports on TMO. Cantor Fitzgerald started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, May 18th. They issued an overweight rating and a $194.00 price target on the stock. Cowen and Company reissued an outperform rating and issued a $185.00 price target (up previously from $175.00) on shares of Thermo Fisher Scientific in a research note on Saturday, April 29th. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $186.00 to $192.00 and gave the company an overweight rating in a research note on Friday, April 28th. Leerink Swann set a $187.00 price target on shares of Thermo Fisher Scientific and gave the company a buy rating in a research note on Thursday, April 27th. Finally, BidaskClub raised shares of Thermo Fisher Scientific from a buy rating to a strong-buy rating in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $187.88.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded up 0.13% during trading on Monday, hitting $181.79. 384,553 shares of the company were exchanged. Thermo Fisher Scientific has a 12 month low of $139.07 and a 12 month high of $182.86. The firm’s 50-day moving average price is $176.35 and its 200 day moving average price is $162.18. The firm has a market capitalization of $71.12 billion, a PE ratio of 33.16 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 26th. The medical research company reported $2.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.02 by $0.06. Thermo Fisher Scientific had a net margin of 11.58% and a return on equity of 15.73%. The firm had revenue of $4.77 billion for the quarter, compared to analysts’ expectations of $4.68 billion. During the same quarter last year, the company earned $1.80 EPS. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts expect that Thermo Fisher Scientific will post $9.23 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/thermo-fisher-scientifics-nysetmo-overweight-rating-reaffirmed-at-barclays-plc/1454533.html.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.95%.

In other news, insider Daniel P. Shine sold 4,688 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total transaction of $805,773.44. Following the transaction, the insider now owns 29,200 shares in the company, valued at approximately $5,018,896. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas W. Loewald sold 1,532 shares of Thermo Fisher Scientific stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $168.76, for a total value of $258,540.32. Following the transaction, the insider now owns 41,277 shares in the company, valued at approximately $6,965,906.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,720 shares of company stock worth $4,960,764. 0.49% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mizuho Securities USA LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at approximately $6,752,000. Brightworth bought a new position in Thermo Fisher Scientific during the second quarter valued at approximately $209,000. Terra Nova Asset Management LLC raised its position in Thermo Fisher Scientific by 2.8% in the second quarter. Terra Nova Asset Management LLC now owns 4,771 shares of the medical research company’s stock valued at $832,000 after buying an additional 131 shares in the last quarter. Dubuque Bank & Trust Co. raised its position in Thermo Fisher Scientific by 344.9% in the second quarter. Dubuque Bank & Trust Co. now owns 1,535 shares of the medical research company’s stock valued at $268,000 after buying an additional 1,190 shares in the last quarter. Finally, Howard Capital Management bought a new position in Thermo Fisher Scientific during the second quarter valued at approximately $8,264,000. Institutional investors and hedge funds own 86.93% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.